Mobile Visits in Decentralized Clinical Trials: The Past, Present and Future


Sponsored Content

In March 2024, the US FDA issued its guidance, “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” outlining the agency’s objectives for protecting public health as artificial intelligence (AI) and other technologies become more prevalent in healthcare.

© 2024 MJH Life Sciences

All rights reserved.